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Abstract
Introduction: Atrial tachyarrhythmias especially atrial ﬁbrillation are the most commonly encountered arrhythmias in
clinical practice. Most atrial tachyarrhythmia episodes are subclinical. Cardiac implantable electronic devices with atrial
sensing function enable detection of atrial tachyarrhythmias through means of atrial high rate event algorithms. Prolonged atrial high rate episodes(AHRE) above a deﬁned rate and duration threshold represent episodes of atrial
ﬁbrillation, atrial ﬂutter, and longer atrial tachycardias that correlate strongly with risk for thromboembolic events.
Objective: 1. To examine the occurrence of prolonged AHRE in dual-chamber pacemaker recipients over the study
period. 2. To examine the factors which inﬂuence the occurrence of prolonged AHRE in these patients.
Methods: In this study, we analyzed data of 398 patients without valvular heart disease or history of atrial ﬁbrillation
who underwent dual chamber permanent pacemaker implantation at our center from January 2013 to June 2018. Patient
demographics, cardiovascular co-morbidities, medications, echocardiographic parameters such as ejection fraction and
left atrial(LA) dimension were obtained. Also, we collected pacing characteristics such as paced QRS duration(QRSd),
ventricular pacing site and cumulative percentage ventricular paced beats.
Results: Prolonged AHRE occurred in 59 patients(14.8%). Baseline LA dimension was greater in patients with prolonged AHRE(median 35 mm, IQR 33e37 vs median 35 mm, IQR 34e38, P ¼ 0.004) compared to those without. Paced
QRSd was signiﬁcantly longer in patients with prolonged AHRE (median of 147 ms, IQR 139e160 ms vs 140 ms, IQR
132e150 ms; P < 0.001). On multivariable logistic regression, paced QRSd(OR 1.04, 95%CI 1.02e1.06; P ¼ 0.001) and
baseline LA dimension(OR 1.14, 95%CI 1.03e1.27; P ¼ 0.01) signiﬁcantly co-predicted AHRE. On Kaplan Meier analysis,
patients with paced QRSd≥142 ms had more likelihood of developing prolonged AHRE during follow up (HR 2.46, CI
1.40e4.3, P ¼ 0.001). After adjusting for baseline values, patients with paced QRSd≥142 ms had signiﬁcant decline in left
ventricular ejection fraction (adjusted mean difference ¡1.27%; P ¼ 0.02) and signiﬁcant LA dilation (adjusted mean
difference 0.62 mm; P ¼ 0.05)
Conclusion: In our study, paced QRSd and LA dimension were the strongest predictors for prolonged AHRE. The
incidence of AHRE may be reduced by achieving the narrowest possible paced QRSd during device implantation.
Keywords: Device detected atrial high rate episodes, Device detected atrial arrhythmia, Sub-clinical atrial ﬁbrillation

1. Introduction
trial tachyarrhythmias (atrial ﬁbrillation,
atrial ﬂutter, and atrial tachycardia) are
commonly encountered arrhythmias in clinical
practice. Among these, atrial ﬁbrillation(AF) is the

A

most common [1,2] and clinically relevant
arrhythmia with a global prevalence of 1e2%. AF is
strongly associated with thromboembolic events(especially ischemic stroke), worsening of left
ventricular(LV) function and worsening cardiac
status [3]. Additionally, AF is associated with
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worsening quality of life, increased hospital admissions and signiﬁcant health-care costs [4]. Most
AF episodes are subclinical and asymptomatic.
Nevertheless, the clinical importance of these difﬁcult to detect asymptomatic AF episodes cannot be
underestimated as subclinical AF (SCAF) episodes
are associated with an increased risk of stroke [5].
Cardiac Implantable Electronic Devices (CIED)
with atrial sensing function enable us to detect and
analyze these atrial tachyarrhythmias. Modern
Atrial High Rate Episode (AHRE) detection algorithms integrated into pacemakers & other CIEDs
allow detection of atrial tachyarrhythmias(AT) with
high sensitivity and speciﬁcity [6,7]. In addition to
ATs, AHRE algorithms may also pick up other
events such as myopotentials, lead noise & pacemaker mediated arrhythmic events such as repetitive non-re-entrant ventriculoatrial synchrony
(RNRVAS), endless loop tachycardia (ELT), far-ﬁeld
R wave (FFRW) [8] which are easily identiﬁable by
evaluating device stored tracings. Various studies
have deﬁned thresholds for the rate and duration
for AHRE episodes that help to differentiate prolonged AHREs from sinus tachycardia, slower &
shorter atrial tachyarrhythmias which are of unknown clinical signiﬁcance. Employing these rate
and duration thresholds, the studies have also been
able to correlate prolonged AHRE with thromboembolic risk [5,9e12]. More recently, there is evidence that prolonged AHRE increases the risk of all
major cardiovascular outcomes(MACE) [13]. Thus,
CIED detected AHRE is emerging as a powerful tool
in the arsenal of the clinician to predict the risk of
such events. Prolonged AHREs above the deﬁned
threshold represent clinically relevant episodes of
atrial ﬁbrillation [14], atrial ﬂutter, and longer atrial
tachycardias which lead to cardioembolic and cardiovascular events. The thresholds used for prolonged AHREs in previous studies and the
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corresponding risk of thromboembolism have been
summarized in Table 1.
Age, previous history of AF, left ventricular function, left atrial size [18], the cumulative percentage
of ventricular paced beats [19,20] and more recently
inﬂammatory markers [21] have been independently associated with AHREs in previous studies.
1.1. Aim of the study
In this retrospective study, we sought to examine
the occurrence of prolonged AHRE in patients undergoing dual chamber permanent pacemaker

Table 1. Summary of trials on AHREs detected by CIED and risk of thromboembolism(adapted from EHRA consensus document on device detected
atrial tachyarrhythmias)[15].
Year

Name of trial

Number of
participants(N)

Follow up
(Months)

AHRE rate cut off
(beats per minute)

AHRE duration
cut off (minutes)

HR for TE event

P-value

2003
2005
2009
2012
2012
2014
2019

Ancillary MOST[9]
AT500 registry[10]
TRENDS[16]
HomeMonitor CRT[11]
ASSERT[5]
SOS AF[12]
Miyazawa et al.[17]

312
725
2486
560
2580
10016
856

27(median)
22(median)
17(mean)
12(median)
30(mean)
24(median)
48(mean)

>220
>174
>175
>180
>190
>175
>175

5
1440
330
228
6
60
5

6.7
3.1
2.2
9.4
2.5
2.11
3.40

0.02
0.04
0.06
0.006
0.007
0.008
0.01

AHRE- Atrial high rate episode, HR e Hazard ratio, TE e Thromboembolic, MOST- Mode selection trial, TRENDS e The relationship
between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke, CRT e cardiac resynchronization therapy,
ASSERT e Asymptomatic atrial ﬁbrillation and stroke evaluation in pacemaker patients and atrial ﬁbrillation reduction atrial pacing trial

implantation at a high-volume center in south India.
Also, we sought to examine the factors which inﬂuence the occurrence of prolonged AHREs.

2. Materials and methods
2.1. Deﬁnitions
a) Atrial tachyarrhythmia e is a collective term which includes
atrial ﬁbrillation, atrial ﬂutter, and atrial tachycardia
b) Prolonged AHRE - From a review of literature, these indicate
AHRE episodes above a certain rate and duration threshold.
These represent episodes of atrial ﬁbrillation, atrial ﬂutter or
longer atrial tachycardias. These episodes have been strongly
linked with the risk of thromboembolism (see Table 1). For
this study, we considered AHREs with any of the following
characteristics as signiﬁcant
i. AHRE occurring at a rate of 220bpm and lasting 
5 min
ii. AHRE occurring at a rate of 190bpm and lasting
6 min
iii. AHRE occurring at a rate of 175bpm and lasting
60 min
c) Virtual CHA2DS2VASc score e The determined CHA2DS2VASc score in the absence of atrial ﬁbrillation

2.2. Study design
We conducted a retrospective study of patients
who underwent dual chamber permanent pacemaker implantation at our center over a period of 5
½ years (January 2013 to June 2018). Data was
collected from admission & discharge records,
inpatient & outpatient medical records and pacemaker interrogation records.
Baseline and demographic data such as age at
implantation, gender, pacemaker indication, cardiac
comorbidities, previously diagnosed AF, presence of
moderate to severe valvular heart disease, drug
history, virtual CHA2DS2VASC score, ejection
fraction, left atrial (LA) dimension, right ventricular
(RV) pacemaker lead position based on chest x-ray
in posteroanterior and lateral view, pacemaker
mode and paced QRS duration were collected.
Medical records and pacemaker interrogation reports were reviewed and information such as AHRE
episodes, cumulative percentage of paced ventricular beats, ejection fraction (biplane Simpson's
method) & LA dimension was collected.
At our center, we routinely implant RV leads in
non-apical positions (such as the lower, upper
septum or the outﬂow tract septum) in preference to
the RV apical position if permitted by pacing
thresholds. Right atrial leads are usually placed in
RA appendage or high right atrial free wall. AV
hysteresis, managed ventricular pacing, Search
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AVþ or other dedicated RV pace reduction algorithms are not generally used at our institution.
Paced AV delay is usually set between 170 and
220 ms. Sensed AV delay is usually set between 150
and 200 ms. A post-procedure ECG is obtained on
the ﬁrst postoperative day while applying a magnet
over the device to document the paced QRS
duration.
2.3. Inclusion criteria
a) Consecutive patients aged more than 17 years who underwent dual chamber permanent pacemaker implantation(DDD or DDDR mode) at our center over the study
period.
b) Patients who had follow-up visits at our center during the
study period with the most recent visit at least 1 year after
pacemaker implantation

2.4. Exclusion criteria
Previously diagnosed atrial ﬁbrillation
History of anticoagulation use
Moderate or severe valvular heart disease
Incomplete medical records or pacemaker interrogation
reports
e) Episodes detected within 48 h of device implantation were
ignored as they could be related to atrial lead implantation.

a)
b)
c)
d)

2.5. Ethics
This is a retrospective study. Institutional ethical
clearance was obtained prior to commencement of
study and data collection. All electronic patient data
was stored in a password-protected computer. Only
the principal and co-investigator had access to any
of the patient data collected for the purpose of this
study.
2.6. Statistical analysis
Categorical variables were described using frequencies and percentages. Continuous variables
were described using mean & standard deviation
(normally distributed data) and median & interquartile range (non-normally distributed data).
Shapiro Wilk test of normality was used to differentiate between normal and non-normal distribution. Categorical data were compared using the chisquare test. Independent samples T-test was used to
compare parametric data. Non-parametric data
were compared using Mann Whitney U test. Univariable logistic regression was used to determine
the association of various variables with the detection of AHRE. The variables with signiﬁcant
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Fig. 1. Study design. VHD e Valvular heart disease, AF e Atrial ﬁbrillation, OAC e Oral anticoagulant.

association were used in a multivariable binary logistic regression to obtain their adjusted association
with the detection of AHRE. Analysis of covariance
(ANCOVA) was used to compare the effect of QRS
duration on ejection fraction (EF) and left atrial (LA)
to control for the baseline values. Kaplan Meier plot
was used to assess the hazard of development of
prolonged AHRE over the study period. A 5% level
of signiﬁcance was considered to be signiﬁcant in all
the analyses. All statistics were done using SPSS
version 23(IBM corporation, USA).

3. Results
3.1. Patient demographics
A total of 564 patients underwent dual chamber
permanent pacemaker implantation at our center
over the study period. 92 patients were excluded
owing to insufﬁcient records. 42 were excluded for
moderate to severe valvular heart disease on echocardiogram and 32 were excluded for prior documentation of AF or anticoagulation use (Fig. 1).
The most common indication for pacing was
symptomatic bifascicular block (27.1%) followed by
complete heart block (26.4%). Sinus node dysfunction accounted for 20.4% of pacemaker implantation
at our center. Other indications for pacing included
Mobitz type II AV block(10.8%), symptomatic

trifascicular block(8.3%) and high-grade AV
block(5.5%).
The mean age of patients in the cohort was 59.89
years (SD e11.93). The majority of our patient
population were males (72.6%). The median duration of follow up was 18.58 months (IQR,
13.22e30.75).
3.2. Baseline characteristics (Table 2)
We compared the baseline & pacing characteristics between patients who were detected to have
prolonged AHRE against those patients who did
not. The baseline variables were comparable across
both groups except for the median baseline LA
dimension which was signiﬁcantly greater in patients with AHRE (35, IQR 34e38 vs 35, IQR 32e36; P
¼ 0.004).
3.3. Post pacing characteristics and cumulative
pacing percentage on follow-up (Table 2)
We also compared the post pacing characteristics
among both the groups. The median paced QRS
duration was signiﬁcantly prolonged in patients
with signiﬁcant AHRE (147, IQR 139e160 vs
140(132.75e150; P < 0.001). Other variables did not
vary signiﬁcantly between both groups.

Table 2. Comparison of baseline & pacing characteristics between patients with and without prolonged AHRE.
Variables

Total (N ¼ 398)

AHRE (N ¼ 59)

No AHRE (N ¼ 339)

P-value

Age (mean, SD)
Males (n, %)
Diabetes Mellitus (n, %)
Hypertension (n, %)
Dyslipidemia (n, %)
CHA2DS2VASc (median, IQR)
Aspirin use (n, %)
Statin use (n, %)
Beta blocker use (n, %)
Ejection fraction (median, IQR)
LA dimension (median, IQR, mm)
Paced QRS duration (median, IQR, ms)
Apical RV lead position (n, %)
Cum. %V paced (median, IQR)

59.89(11.93)
289 (72.6)
142(35.7)
245(61.6)
192(48.2)
2(1e3)
103(25.9)
158(39.7)
92(23.1)
57(56e59)
35(33e37)
142(134e152)
99(24.9)
67(5e99)

61.46(12.82)
40 (73.5)
23(39)
37(62.7)
23(39)
2(1e3)
19(32.2)
24(40.7)
16(27.1)
57(56e59)
35(34e38)
147 (139e160)
20(33.9)
92(17e99)

59.62(11.77)
249(67.8)
119(35.1)
208(61.4)
169(49.9)
2(1e3)
84(24.8)
134(39.5)
76(22.4)
57(56e59)
35(32e36)
140(132.75e150)
79(23.3)
62(3e99)

0.28
0.43
0.56
0.89
0.16
0.11
0.26
0.89
0.41
0.78
0.004
<0.001
0.10
0.17

3.4. Predictors of prolonged AHRE during followup (Table 3)

4%. Every 1 mm increase in LA dimension increased
the risk of prolonged AHRE by 14%.

On follow up, device detected prolonged AHRE
occurred in 59 patients (14.8%). Univariable logistic
regression analysis (Table 3) revealed that among
the various factors, baseline LA dimension (OR 1.17,
CI 1.06e1.29; P ¼ 0.002), paced QRS duration (OR
1.04, CI 1.02e1.07; P < 0.001) & cumulative percentage of ventricular pacing (OR 1.07, CI 1.0e1.14,
P ¼ 0.05) signiﬁcantly predicted prolonged AHRE
episodes.

3.6. Paced QRS duration and hazard of AHRE
(Fig. 2)

3.5. Adjusted predictors of prolonged AHRE during
follow-up (Table 4)
After adjusting for other factors, baseline LA
dimension and paced QRS duration (QRSd) were
signiﬁcant co-predictors for prolonged AHRE episodes. Every 1 ms prolongation of paced QRS
duration increased the risk of prolonged AHRE by

Table 3. Univariable logistic regression analysis looking at the unadjusted association of various variables to the detection of prolonged
AHRE.
Variables

OR

95% CI

Age
Gender(male)
Diabetes Mellitus
Hypertension
Dyslipidemia
CHA2DS2VASc
Aspirin use
Statin use
Beta blocker use
Ejection fraction
Baseline LA dimension
Paced QRS duration
Lead position(apical)
Cum. %V paced

1.01
1.31
1.18
1.06
0.64
1.15
1.44
1.05
1.29
1.02
1.17
1.04
1.69
1.07

0.99
0.72
0.67
0.60
0.37
0.94
0.79
0.60
0.69
0.95
1.06
1.02
0.93
1.00

P-value
1.04
2.39
2.09
1.88
1.13
1.40
2.63
1.84
2.41
1.10
1.29
1.07
3.06
1.14

0.27
0.37
0.57
0.84
0.13
0.18
0.23
0.87
0.43
0.55
0.002
<0.001
0.09
0.05

As QRS duration was found to signiﬁcantly predict the risk of prolonged AHRE, we decided to
examine the association of a longer paced QRS
duration (50th percentile for the cohort,  142 ms)
on the hazard of developing signiﬁcant AHRE during follow-up. Patients who had a paced
QRSd142 ms were more likely to have a prolonged
AHRE episode (P ¼ 0.001) over the period of follow
up.
3.7. Paced QRSd and its effect on EF & LA
dimension(Table 5)
Even after correcting for baseline values, there
was signiﬁcant decrease in EF in patients with paced
QRS duration  142 ms (adjusted mean difference
1.27, P ¼ 0.01). Also, after correcting for baseline
values, there was signiﬁcant increase in LA dimension in patients with paced QRS duration 142 ms
(adjusted mean difference 0.62, P ¼ 0.05)

4. Discussion
This study was designed to look at the incidence
of prolonged AHRE in pacemaker patients and

Table 4. Multivariable logistic regression looking at the adjusted association of signiﬁcant variables to the detection of prolonged AHRE.
Variables

OR

95% CI

Paced QRS duration
Baseline LA dimension
Cum. %V paced

1.04
1.14
1.04

1.02
1.03
0.97

P-value
1.06
1.27
1.12

0.001
0.01
0.30
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Fig. 2. Kaplan Meier hazard plot showing the likelihood of AHRE in pacemaker patients with paced QRS duration >142 ms as compared to those with
less than 142 ms. HR e Hazard ratio, CI e Conﬁdence interval.

further analyze its relationship to other factors.
Prolonged AHRE episodes were detected in 59 patients (14.8%). This was lower than in most previous
studies. This may be due to several reasons.
 Our study completely excluded patients who had moderate
to severe valvular heart disease involving any valve. Most of

the previous studies have not explicitly excluded moderate/
severe valvular heart disease in their study protocol. Unlike
the other populations in whom comorbidities such as hypertension & diabetes constitute the dominant risk factors for
AF, in India up to 40% of AF burden is attributable to
valvular heart disease [23].
 Our study also excluded patients with previously diagnosed
AF. In unselected studies, the detection of AHRE has been

Table 5. Analysis of covariance for assessing the relation between paced QRS and changes in EF & LA dimension after adjusting for baseline values.
Variable

EF (%) at follow up
LA dimension(mm)
at follow up

Observed mean

Adjusted mean

QRSd142 ms

QRSd142 ms

QRSd142 ms
QRS>142

QRSd 142msaced
QRS<142

54.80
36.83

56.59
35.63

55.06
36.54

56.33
35.92

Adjusted
mean
difference

Confidence
interval

P-value

1.27
0.62

2.34
0.01

0.02
0.05

0.20
1.24

reported to be as high as 50%. Past history of AF has been
found in as much as 63% of the study population in prior
studies [9,24,25]. In fact, this may have inﬂuenced the results
to such an extent that AF history was the only signiﬁcant
predictor of device detected AF in one such study [24]. In
studies where past AF was excluded the incidence of device
detected AHRE has been much more conservative in the
range of 24e35% [5,19,26].
 The mean age at pacemaker implantation in our study population was 59.89(SD e11.93). In comparison, the mean age of
device implantation in previous AHRE studies (derived from
the meta-analysis by Mahajan et al.) [27] was 72(IQR, 65e77).
AF being a disease of the elderly is likely to be less common in
a younger study population such as ours. A decade difference
in the onset of degenerative conduction system disease in our
population is an interesting topic for future research.

Next, we looked at the association of prolonged
AHRE with various variables after adjustment for
various cofactors using multivariable logistic
regression. Here paced QRS duration (OR 1.04, CI
1.02e1.06, P ¼ 0.001), and baseline LA dimension
(OR 1.14, CI 1.03e1.27, P ¼ 0.01) stood out as signiﬁcant. LA enlargement has been debated as both a
cause and effect of atrial ﬁbrillation [28]. Nevertheless, there is a strong association between LA
enlargement and risk of AF [29]. In the Framingham
heart study, for every 1 mm increase in the LA
dimension, there was an increase in the risk of AF
by 8% [30]. Our study also arrived at the same
conclusion.
The QRS duration is a measure of the degree of
ventricular dyssynchrony. In several previous
studies, prolonged paced QRSd has been shown to
be associated with worsening LV function. [31e33]
In our study, QRSd has also been shown to be
associated with prolonged AHRE in pacemaker recipients. A recent study by Xing et al. [34] arrived at
the same conclusion. This is of immense clinical
importance. Paced ECG is easily available and
achieving a QRS as narrow as possible has been
traditionally used as a goal to guide optimal lead
placement. In most cases, non-apical lead placement such as septal, RV outﬂow tract (RVOT) and
His Bundle area (HBA) leads to shorter QRS durations. This has been done in hopes of restoring
ventricular synchrony and preserving LV function.
However, our study shows that this strategy also
reduces the rates of AHRE; thus, accentuating the
potential beneﬁt of non-apical pacing. In fact, a
study by Pastore et al. [35] revealed that HBA pacing
led to a lower occurrence of AF on follow up over a
period of 5 years.
Finally, we also looked at the changes in EF & LA
dimension and their relation to paced QRS duration.
As seen in previous studies, there was a signiﬁcant
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decline in LV function (adjusted mean difference
1.27, P ¼ 0.01) with broadening of QRS implying
the importance of ventricular dyssynchrony in promoting LV dysfunction. Also, there was signiﬁcant
LA enlargement (adjusted mean difference 0.62, P ¼
0.05) among patients with QRSd142 ms. LA
remodeling and LA dilation are critical pathogenetic
factors promoting & maintaining AF. This ﬁnding
highlights the role of ventricular dyssynchrony in
promoting LA remodeling.
Implanted devices give us a unique opportunity to
diagnose atrial tachyarrhythmias early. A recent
meta-analysis that combines evidence from 11
major trials show that the relationship between
device detected atrial tachyarrhythmias and stroke
risk is unequivocal (OR 2.4, CI 1.8e3.3, P < 0.001)
[27]. Prolonged AHRE has also been identiﬁed as an
independent predictor of subclinical silent ischemic
brain lesions [36]. However, the adoption of anticoagulation in this patient population is low [18]. A
recent small scale study looked into the efﬁcacy and
safety of oral anticoagulation in patients with prolonged AHRE [37]. The study concluded that OAC
therapy was not associated with an increase in
major bleeding. Two large scale studies [38,39] are
underway examining the safety and efﬁcacy of OAC
therapy in patients with prolonged AHRE. The
EHRA consensus document on device detected
subclinical atrial tachyarrhythmias recommends
consideration of anticoagulation for all patients with
prolonged AHRE and CHA2DS2VASc score 2[15].
4.1. Limitations of the study
Our study has a few limitations. First of all, it is a
retrospective study. Also, there is a heterogeneity in
the indications for device implantation in the study
population. Further, we did not assess the cumulative burden of AHRE in each individual which has
been previously shown to correlate with stroke risk
[16]. It is possible that patients with subclinical AF
prior to device implantation may have been
included in the analysis e however, there is no
reliable method to exclude such patients. We have
measured LA dimension instead of the more reliable indexed LA volume (the former underestimates
LA enlargement as it measures it along one axis
only). There is new evidence that AHRE detected up
to 3 months post-implantation may be related to the
atrial lead ﬁxation used and the procedure itself
without a signiﬁcant effect on clinical outcomes [22].
However, we have not excluded such episodes from
our study as our study protocol was ﬁnalized before
this paper was published. Also, dedicated
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algorithms to reduce RV pacing such as managed
ventricular pacing, Search AVþ are not generally
used in our institution. Therefore, the potential
beneﬁt of these algorithms in reducing AHRE will
not reﬂect in this study. Lastly, no outcome measures such as stroke were included in this study.

5. Conclusion
In pacemaker implanted patients without valvular
heart disease or history of atrial ﬁbrillation, prolonged
AHREs are mainly predicted by paced QRS duration
and left atrial dilation. Achieving the narrowest
possible QRS duration during implantation by
optimal non-apical lead positioning and increasing
adoption of His-Bundle area pacing strategy can
potentially decrease pacemaker detected atrial
tachyarrhythmias in addition to preserving LV
function.

Future directions
The adoption of more physiological pacing strategies is likely to decrease the risk of AHRE post
pacemaker implantation. Further studies examining
the occurrence of AHRE with physiological pacing
protocols are required. Although the correlation
between device detected AHRE and stroke risk is
robust, there are still major gaps in our understanding with regard to the pathophysiologic basis
of AT leading to stroke, the temporal relationship of
stroke with AHRE as well as appropriate use and
safety of oral anticoagulation for device detected
AHRE. The ongoing trials such as ARTESiA [39]
(Apixaban for the Reduction of Thrombo-Embolism
in patients with Device-Detected Sub-Clinical
Atrial
ﬁbrillation,
ClinicalTrials.govIdentiﬁer:
NCT01938248) and NOAH-AFNET 6 [38] (Nonvitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate EpisodesdAtrial
Fibrillation NETwork6,ClinicalTrials.gov Identiﬁer:
NCT02618577) are likely to shed more light on
appropriate management of device detected AHRE.
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